Wall Street analysts forecast that HCA Healthcare (HCA) will report quarterly earnings of $4.97 per share in its upcoming release, pointing to a year-over-year increase of 27.1%. It is anticipated that revenues will amount to $17.49 billion, exhibiting an increase of 7.9% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reasse ...

Michael (Mike) Dion is an FP&A, Corporate Finance, and Small Business expert who spent the last 12 years working in the Fortune 100, building a startup's finance and accounting department, advising small businesses, and guiding non-profit organizations as a board member. He has finance experience across multiple industries, including Telecom, Media and Entertainment, Hospitality, and Construction. He founded F9 Finance, a website that helps Finance professionals accelerate their careers; and simplifies Fina ...

Group 1: HCA Healthcare - HCA Healthcare is a leading hospital chain in the U.S. with 186 hospitals and over 2,000 care centers, demonstrating strong market share growth from 24% in 2012 to 27% a decade later [2][3] - The company has successfully navigated challenges such as managing medical facilities and economic issues, resulting in strong financial performance alongside market share gains [3] - HCA plans to continue investing in facilities and services, targeting a 29% market share by 2030, indicating a proven strategy in a competitive industry [3] Group 2: Vertex Pharmaceuticals - Vertex Pharmaceuticals has a strong portfolio focused on cystic fibrosis treatments, being the only company that markets medicines addressing the underlying causes of the condition [4][5] - The company is expanding beyond cystic fibrosis with the recent approval of Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia, which is expected to contribute significantly to revenue [5] - Vertex is awaiting approval for new products and has ongoing clinical trials, positioning the company for potential clinical successes and better-than-average returns through the end of the decade [5][6]

HCA Healthcare (HCA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 25, 2024, might help the stock move higher if these key numbers are better ...

One company that I have been consistently bullish about over the past few years is HCA Healthcare (NYSE: HCA ). If you're not familiar with the company, the most important thing to know about it is that it is Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential. Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P fi ...

The U.S. hospital industry has been in fine fettle over the past year. The industry has been witnessing several positive catalysts such as rising admissions, the resumption of elective procedures, cybersecurity and other technological advancements. The Zacks-defined Medical – Hospital Industry is currently in the top 1% of the Zacks Industry Rank. In the past year, the industry has provided a massive 61.1% return, while its year-to-date return is also impressive at 50.6%. Since it is ranked in the top half ...

HCA Healthcare (HCA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a ch ...

One stock that might be an intriguing choice for investors right now is HCA Healthcare, Inc. (HCA) . This is because this security in the Zacks Medical – Hospital space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in t ...

Core Insights - Zacks Premium offers various tools for investors to identify stocks to buy, sell, and track hot industries [1] - The Focus List is a curated portfolio of 50 stocks aimed at long-term investors, expected to outperform the market over the next 12 months [3][4] Performance Metrics - The Focus List gained 13.85% in 2020, outperforming the S&P 500's return of 9.38% [5] - Cumulatively, the Focus List has returned 2,519.23% from February 1, 1996, to March 31, 2021, compared to the S&P's 854.95% [5] Methodology - Stocks for the Focus List are selected based on earnings estimate revisions, which reflect analysts' expectations of growth and profitability [6][7] - The Zacks Rank, a proprietary stock-rating model, uses changes in quarterly earnings expectations to help investors build a successful portfolio [8] Zacks Rank Factors - The Zacks Rank is based on four main factors: Agreement, Magnitude, Upside, and Surprise, which are recalculated nightly [9] - Stocks in the Focus List are primarily from 1 (Strong Buy) or 2 (Buy) ranked companies, indicating a bullish earnings consensus among analysts [9] Case Study: HCA Healthcare - HCA Healthcare, the largest non-governmental operator of acute care hospitals in the U.S., has seen its stock increase by 227.03% since being added to the Focus List [10][11] - The Zacks Consensus Estimate for HCA's fiscal 2024 earnings has increased by $1.49 to $22.46, with an expected earnings growth of 18.2% for the current fiscal year [11]

HCA Healthcare, Inc. (HCA) shares have gained 18.4% in the past three months, outperforming the hospital industry and the S&P 500 Index. Over this time frame, the industry and the S&P 500 Index have gained 16% and 2.2%, respectively. Currently priced at $403.43, the stock is less than 1% below its 52-week high. This proximity underscores investor confidence and market optimism about this hospital company's prospects. Moreover, the stock is trading above its 50-day and 200-day moving averages, signaling stro ...